Table 4 Clinical outcome variables
|  | Placebo (n = 30) | Dexmedetomidine (n = 30) | P |
|---|---|---|---|
Use of sedatives during study-drug infusion, n (%) | 1 (3.3) | 3 (10.0) | 0.601 |
Propofol | 0 (0.0) | 1 (3.3) | Â |
Midazolam | 1 (3.3) | 2 (6.7) | Â |
Use of opioids during study-drug infusion, n (%) | 6 (20.0) | 5 (16.7) | > 0.999 |
Remifentanil | 1 (3.3) | 1 (3.3) | Â |
Butorphanol | 5 (16.7) | 4 (13.3) | > 0.999 |
RASS at the end of study-drug infusion, median (IQR) | 0 (0–0) | 0 (0–0) | > 0.999 |
Subjective pain score on postoperative day one, median (IQR) | 4 (0–6) | 3 (2–4) | 0.192 |
Subjective sleep score on postoperative day one, median (IQR) | 5 (2–9) | 2 (1–7) | 0.142 |
Time to extubation,* median (IQR), hours | 17 (16–19) | 18 (15–19) | > 0.999 |
Non-delirium complications, n (%) | 7 (23.3) | 4 (13.3) | 0.506 |
Length of stay in the ICU, median (IQR), hours | 17 (15–19) | 18 (16–19) | 0.376 |
Length of stay in hospital after the operation, median (IQR), days | 9 (8–12) | 11 (8–15) | 0.247 |
Mini-Cog at the end of follow-up, median (IQR) | 5 (4–5) | 5 (4–5) | 0.507 |